218 related articles for article (PubMed ID: 32448667)
21. Developing multiple lung nodules in a renal transplant recipient with tuberous sclerosis who had undergone bilateral nephrectomy due to renal cell carcinomas.
Saito M; Yuasa T; Satoh S; Nanjo H; Tsuchiya N; Habuchi T
Int J Urol; 2008 Mar; 15(3):257-8. PubMed ID: 18304223
[TBL] [Abstract][Full Text] [Related]
22. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
[TBL] [Abstract][Full Text] [Related]
26. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
Coombs EJ
J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
[TBL] [Abstract][Full Text] [Related]
27. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.
Janssens P; Van Hoeve K; De Waele L; De Rechter S; Claes KJ; Van de Perre E; Wissing KM; Bammens B; Jansen A; Mekahli D
Pediatr Nephrol; 2018 Nov; 33(11):2085-2093. PubMed ID: 29987458
[TBL] [Abstract][Full Text] [Related]
28. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
[TBL] [Abstract][Full Text] [Related]
29. Tuberous sclerosis complex with end-stage renal failure.
Neumann HP; Brüggen V; Berger DP; Herbst E; Blum U; Morgenroth A; Schollmeyer P; Wetterauer U
Nephrol Dial Transplant; 1995; 10(3):349-53. PubMed ID: 7792029
[TBL] [Abstract][Full Text] [Related]
30. A single-center 4-year experience with 47 pediatric renal transplants: Evolving trends.
El Hennawy HM; Al Hashemy A; Al Harbi N; Habhab WT; Fahmy AE
Saudi J Kidney Dis Transpl; 2018; 29(6):1303-1310. PubMed ID: 30588960
[TBL] [Abstract][Full Text] [Related]
31. Update on the Diagnosis and Management of Renal Angiomyolipoma.
Flum AS; Hamoui N; Said MA; Yang XJ; Casalino DD; McGuire BB; Perry KT; Nadler RB
J Urol; 2016 Apr; 195(4 Pt 1):834-46. PubMed ID: 26612197
[TBL] [Abstract][Full Text] [Related]
32. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
[TBL] [Abstract][Full Text] [Related]
33. Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC).
Machacek ME; Wu CL; Cornejo KM
Semin Diagn Pathol; 2024 Jan; 41(1):8-19. PubMed ID: 37993384
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment with sirolimus for an angiomyolipoma mimicking renal cell carcinoma in a transplanted kidney.
Chiu HF; Wen MC; Li JR; Ho HC; Shu KH
Transpl Int; 2015 Sep; 28(9):1116-20. PubMed ID: 25790294
[TBL] [Abstract][Full Text] [Related]
35. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition.
Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T
BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
37. The impact of renal angiomyolipoma on estimated glomerular filtration rate in patients with tuberous sclerosis complex.
Seyam R; Khudair WA; Kattan SA; Al Otaibi MF; Skaff F; AlTaweel WM
Ann Saudi Med; 2016; 36(5):356-363. PubMed ID: 27710989
[TBL] [Abstract][Full Text] [Related]
38. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
39. Concurrent Eosinophilic Solid and Cystic Renal Cell Carcinoma and Angiomyolipoma With Epithelial Cysts in the Setting of Tuberous Sclerosis Complex: A Rare Synchronous Occurrence of 2 Distinct Entities.
Cho WC; Collins K; Mnayer L; Cartun RW; Earle JS
Int J Surg Pathol; 2019 Oct; 27(7):804-811. PubMed ID: 31142207
[TBL] [Abstract][Full Text] [Related]
40. Conservative treatment of renal angiomyolipomas in patients with tuberous sclerosis.
Hadley DA; Bryant LJ; Ruckle HC
Clin Nephrol; 2006 Jan; 65(1):22-7. PubMed ID: 16429838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
